328 related articles for article (PubMed ID: 35819632)
21. Recent Updates on the Use of PCSK9 Inhibitors in Patients with Atherosclerotic Cardiovascular Disease.
Dixon DL; Pamulapati LG; Bucheit JD; Sisson EM; Smith SR; Kim CJ; Wohlford GF; Pozen J
Curr Atheroscler Rep; 2019 Mar; 21(5):16. PubMed ID: 30877491
[TBL] [Abstract][Full Text] [Related]
22. Economic evaluation of ezetimibe treatment in combination with statin therapy in the United States.
Davies GM; Vyas A; Baxter CA
J Med Econ; 2017 Jul; 20(7):723-731. PubMed ID: 28426345
[TBL] [Abstract][Full Text] [Related]
23. Modelling the cost-effectiveness of PCSK9 inhibitors vs. ezetimibe through LDL-C reductions in a Norwegian setting.
Korman M; Wisløff T
Eur Heart J Cardiovasc Pharmacother; 2018 Jan; 4(1):15-22. PubMed ID: 28444187
[TBL] [Abstract][Full Text] [Related]
24. Evolocumab for Treating Primary Hypercholesterolaemia and Mixed Dyslipidaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Carroll C; Tappenden P; Rafia R; Hamilton J; Chambers D; Clowes M; Durrington P; Qureshi N; Wierzbicki AS
Pharmacoeconomics; 2017 May; 35(5):537-547. PubMed ID: 28285379
[TBL] [Abstract][Full Text] [Related]
25. Cost-Effectiveness of Icosapent Ethyl (IPE) for the Reduction of the Risk of Ischemic Cardiovascular Events in Canada.
Lachaine J; Charron JN; Gregoire JC; Hegele RA; Leiter LA
Clinicoecon Outcomes Res; 2023; 15():295-308. PubMed ID: 37101608
[TBL] [Abstract][Full Text] [Related]
26. Relationship Between Low-Density Lipoprotein Cholesterol, Free Proprotein Convertase Subtilisin/Kexin Type 9, and Alirocumab Levels After Different Lipid-Lowering Strategies.
Rey J; Poitiers F; Paehler T; Brunet A; DiCioccio AT; Cannon CP; Surks HK; Pinquier JL; Hanotin C; Sasiela WJ
J Am Heart Assoc; 2016 Jun; 5(6):. PubMed ID: 27287699
[TBL] [Abstract][Full Text] [Related]
27. Inclisiran as Adjunct Lipid-Lowering Therapy for Patients with Cardiovascular Disease: A Cost-Effectiveness Analysis.
Kam N; Perera K; Zomer E; Liew D; Ademi Z
Pharmacoeconomics; 2020 Sep; 38(9):1007-1020. PubMed ID: 32789593
[TBL] [Abstract][Full Text] [Related]
28. Cost Effectiveness of Inclisiran in Atherosclerotic Cardiovascular Patients with Elevated Low-Density Lipoprotein Cholesterol Despite Statin Use: A Threshold Analysis.
Desai NR; Campbell C; Electricwala B; Petrou M; Trueman D; Woodcock F; Cristino J
Am J Cardiovasc Drugs; 2022 Sep; 22(5):545-556. PubMed ID: 35595929
[TBL] [Abstract][Full Text] [Related]
29. Cost-effectiveness of lipid lowering with statins and ezetimibe in chronic kidney disease.
Schlackow I; Kent S; Herrington W; Emberson J; Haynes R; Reith C; Collins R; Landray MJ; Gray A; Baigent C; Mihaylova B;
Kidney Int; 2019 Jul; 96(1):170-179. PubMed ID: 31005271
[TBL] [Abstract][Full Text] [Related]
30. A systematic review and economic evaluation of statins for the prevention of coronary events.
Ward S; Lloyd Jones M; Pandor A; Holmes M; Ara R; Ryan A; Yeo W; Payne N
Health Technol Assess; 2007 Apr; 11(14):1-160, iii-iv. PubMed ID: 17408535
[TBL] [Abstract][Full Text] [Related]
31. Cost-Effectiveness of Evolocumab Therapy for Myocardial Infarction: The Chinese Healthcare Perspective.
Liang Z; Chen Q; Yang F; Yan X; Zhang X; Chen X; Fang F; Zhao Q
Cardiovasc Drugs Ther; 2021 Aug; 35(4):775-785. PubMed ID: 33090294
[TBL] [Abstract][Full Text] [Related]
32. Umbrella Review on Non-Statin Lipid-Lowering Therapy.
Beshir SA; Hussain N; Elnor AA; Said ASA
J Cardiovasc Pharmacol Ther; 2021 Sep; 26(5):437-452. PubMed ID: 33836639
[TBL] [Abstract][Full Text] [Related]
33. Implications for REDUCE IT in clinical practice.
Bittner V
Prog Cardiovasc Dis; 2019; 62(5):395-400. PubMed ID: 31715195
[TBL] [Abstract][Full Text] [Related]
34. Lost Therapeutic Benefit of Delayed Low-Density Lipoprotein Cholesterol Control in Statin-Treated Patients and Cost-Effectiveness Analysis of Lipid-Lowering Intensification.
Marquina C; Morton J; Zomer E; Talic S; Lybrand S; Thomson D; Liew D; Ademi Z
Value Health; 2023 Apr; 26(4):498-507. PubMed ID: 36442832
[TBL] [Abstract][Full Text] [Related]
35. Cost-effectiveness of adding ezetimibe to atorvastatin vs switching to rosuvastatin therapy in Portugal.
Laires PA; Ejzykowicz F; Hsu TY; Ambegaonkar B; Davies G
J Med Econ; 2015; 18(8):565-72. PubMed ID: 25788039
[TBL] [Abstract][Full Text] [Related]
36. The cost-effectiveness of PCSK9 inhibitors - The Australian healthcare perspective.
Kumar R; Tonkin A; Liew D; Zomer E
Int J Cardiol; 2018 Sep; 267():183-187. PubMed ID: 29731350
[TBL] [Abstract][Full Text] [Related]
37. A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular outcomes.
Khan SU; Talluri S; Riaz H; Rahman H; Nasir F; Bin Riaz I; Sattur S; Ahmed H; Kaluski E; Krasuski R
Eur J Prev Cardiol; 2018 May; 25(8):844-853. PubMed ID: 29569492
[TBL] [Abstract][Full Text] [Related]
38. PCSK9 inhibitors and ezetimibe for the reduction of cardiovascular events: a clinical practice guideline with risk-stratified recommendations.
Hao Q; Aertgeerts B; Guyatt G; Bekkering GE; Vandvik PO; Khan SU; Rodondi N; Jackson R; Reny JL; Al Ansary L; Van Driel M; Assendelft WJJ; Agoritsas T; Spencer F; Siemieniuk RAC; Lytvyn L; Heen AF; Zhao Q; Riaz IB; Ramaekers D; Okwen PM; Zhu Y; Dawson A; Ovidiu MC; Vanbrabant W; Li S; Delvaux N
BMJ; 2022 May; 377():e069066. PubMed ID: 35508320
[TBL] [Abstract][Full Text] [Related]
39. Cost-effectiveness of PCSK9 inhibition in addition to standard lipid-lowering therapy in patients at high risk for vascular disease.
Stam-Slob MC; van der Graaf Y; de Boer A; Greving JP; Visseren FLJ
Int J Cardiol; 2018 Feb; 253():148-154. PubMed ID: 29306457
[TBL] [Abstract][Full Text] [Related]
40. Long-term Cost-effectiveness of Statin Treatment for Primary Prevention of Cardiovascular Disease in the Elderly.
Lin L; Teng M; Zhao YJ; Khoo AL; Seet RC; Yong QW; Yeo TC; Lim BP
Cardiovasc Drugs Ther; 2015 Apr; 29(2):187-97. PubMed ID: 25860556
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]